Sickle Cell Anemia

Sickle cell anemia is the severe HbSS phenotype within sickle cell disease. Deoxygenated HbS polymerization drives red-cell deformation and initiates vaso-occlusion, hemolysis, chronic anemia, endothelial dysfunction, inflammation, oxidative stress, and cumulative organ injury. ccjmccjm[PDF] Sickle cell disease: A primary care update This mechanism explains why an apparently routine presentation—pain, fever, anemia, hypoxemia, neurologic symptoms, or jaundice—may signal an evolving organ-threatening complication.

A medical-home model linking hematology, primary care, emergency care, pain management, obstetrics when relevant, and organ-specific specialists is clinically important. Adults remain substantially disadvantaged in survival, with life expectancy reported as more than two decades shorter than that of the general population; disease complications increasingly interact with age-related cardiovascular, renal, hepatic, and other comorbidities. ccjmccjm[PDF] Sickle cell disease: A primary care update

Sickle cell disease results from inherited abnormalities involving the beta-globin gene; in sickle cell anemia, HbS arises from substitution of valine for glutamic acid at the sixth beta-globin codon. NEJM+1NEJMCRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemiaccjm[PDF] Sickle cell disease: A primary care update Clinical severity varies across SCD genotypes, and HbSS is generally the most severe phenotype. ASH+1ASHManagement of liver complications in sickle cell diseaseCDCData and Statistics on Sickle Cell Disease | Sickle Cell Disease (SCD) | CDC

At transition to a new clinician or care system, establish the individual baseline against which acute changes will be judged. The available sources support comprehensive complication surveillance but do not provide a sufficiently detailed, source-supported laboratory panel, surveillance interval set, or diagnostic threshold schedule to specify beyond specialty-guided care. BMJ+2BMJSickle cell anemia - Symptoms, diagnosis and treatment | BMJ Best Practice USCDCSickle Cell Information for Healthcare Providers | Sickle Cell Disease (SCD) | CDCccjm[PDF] Sickle cell disease: A primary care update

The supplied evidence summarizes longstanding guideline-based pediatric prevention measures: penicillin prophylaxis for children through age 5 years and annual transcranial Doppler examination from ages 2 through 16 years. NEJMNEJMManaging Sickle Cell Disease: An Update | NEJM Clinician These measures should be embedded in a comprehensive SCD program rather than treated as isolated primary-care tasks.

The search results identify ASH and NHLBI clinical guidance as core U.S. resources for SCD management and describe CDC tools intended to support implementation. CDCCDCSickle Cell Information for Healthcare Providers | Sickle Cell Disease (SCD) | CDC Specific vaccine schedules, Doppler velocity thresholds, and downstream transfusion protocols are not provided in the supplied results and should be verified in the current guideline and local hematology pathway.

Hydroxyurea increases fetal hemoglobin production and has been a central disease-modifying therapy for sickle cell anemia. NEJM+1NEJMCRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaWolters KluwerInnovative Treatments for Rare Anemias : HemaSphere The supplied evidence notes benefit in young children and identifies hydroxyurea among expert-panel treatment recommendations. NEJMNEJMManaging Sickle Cell Disease: An Update | NEJM Clinician However, it does not provide source-supported U.S. initiation doses, titration schedules, laboratory targets, contraindications, or monitoring intervals; these should be taken from current FDA labeling and contemporary hematology guidance rather than inferred.

Therapeutic development has expanded beyond hydroxyurea, including anti-sickling approaches and cellular therapies. PubMedPubMedRecent Advances in the Treatment of Sickle Cell Disease - PubMed Voxelotor demonstrated dose-dependent increases in hemoglobin–oxygen affinity in early clinical development and was evaluated in a phase 3 trial. NEJMNEJMA Phase 3 Randomized Trial of Voxelotor in Sickle Cell ... The supplied results do not establish its current U.S. regulatory status, indication, dose, safety restrictions, or role after later safety and market changes; do not prescribe from this evidence summary alone.

Vaso-occlusion causes severe pain and can lead to organ damage, while hemolysis contributes to chronic anemia. NEJM+2NEJMCRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-ThalassemiaNatureFDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDAccjm[PDF] Sickle cell disease: A primary care update Acute care should therefore assess for complications rather than assuming uncomplicated vaso-occlusive pain. The supplied sources identify analgesia, hydration, transfusion for severe anemia, antibiotic treatment or prevention when infection is relevant, and comprehensive care as components of symptomatic management, but do not provide an evidence-supported acute treatment algorithm or dosing regimen. Wolters KluwerWolters KluwerCRISPR/Cas9 in the treatment of sickle cell disease (SCD)... : Annals of Medicine and Surgery

SCD-associated liver disease has a broad differential. Hepatic injury can arise from intrahepatic sickling and hypoxic injury, transfusion-associated iron overload or viral hepatitis, gallstone-related biliary obstruction, or coincidental hepatic disease. ASHASHManagement of liver complications in sickle cell disease Acute or chronic cholestatic presentations should therefore not be attributed reflexively to hemolysis without evaluating hepatobiliary and transfusion-related causes.

Red-cell transfusion remains an important component of SCD care, including support for severe anemia and selected complications. Wolters KluwerWolters KluwerCRISPR/Cas9 in the treatment of sickle cell disease (SCD)... : Annals of Medicine and Surgery Its use must balance clinical benefit against alloimmunization, hemolytic transfusion reactions, iron overload, and infectious risks. ASH published transfusion-support guidance, and patients with complex transfusion histories should be managed with hematology and transfusion medicine input. BMJ+2BMJSickle cell anemia - Symptoms, diagnosis and treatment | BMJ Best Practice USajogSociety for Maternal-Fetal Medicine Consult Series #68: Sickle cell disease in pregnancyASHManagement of liver complications in sickle cell disease

The FDA approved exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) as the first gene therapies for SCD. Nature+1NatureFDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDAWolters KluwerMedication Update : The Nurse Practitioner Lyfgenia is approved for patients aged 12 years or older with SCD and a history of vaso-occlusive events; it uses autologous hematopoietic stem cells modified with a lentiviral vector to produce HbAT87Q, a hemoglobin designed to reduce red-cell sickling. NatureNatureFDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA Casgevy uses CRISPR/Cas9 editing of autologous hematopoietic stem cells to increase fetal hemoglobin production after reinfusion and engraftment. NatureNatureFDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA

Referral is appropriate when recurrent vaso-occlusive morbidity persists despite optimized conventional care, when transfusion burden or progressive organ injury is substantial, or when the patient seeks evaluation for cellular therapy. Eligibility, conditioning suitability, fertility implications, access, and long-term safety surveillance must be addressed at a specialized transplant or gene-therapy center. The supplied sources do not provide sufficient detail to specify comparative efficacy, conditioning regimens, or patient-level contraindications. Nature+2NatureFDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDAWolters KluwerMedication Update : The Nurse PractitionerCDCSickle Cell Information for Healthcare Providers | Sickle Cell Disease (SCD) | CDC

Pregnant patients with SCD should receive individualized multidisciplinary care involving clinicians with relevant expertise, including hematology, obstetrics, midwifery, pediatrics, and neonatal care as appropriate. ajog+1ajogSociety for Maternal-Fetal Medicine Consult Series #68: Sickle cell disease in pregnancyWHOWHO issues first global guideline to improve pregnancy care for women with sickle cell disease WHO emphasizes preconception or early-pregnancy discussion of treatment choices and plans for anticipated complications. WHOWHOWHO issues first global guideline to improve pregnancy care for women with sickle cell disease For U.S. practice, consult current maternal-fetal medicine and hematology guidance for medication, transfusion, fetal surveillance, and delivery decisions because those details are not supplied here.

Adult transition should preserve the preventive and disease-modifying infrastructure established in childhood. Primary care clinicians are particularly important in maintaining health maintenance, coordinating specialty services, addressing comorbidities, and avoiding fragmentation that can worsen acute-care reliance. ccjmccjm[PDF] Sickle cell disease: A primary care update